Based in Oxford, England, Oxford Sciences Innovation (OSI) specializes in investments in spin-outs from Oxford University’s technology, mathematical, physical, life sciences and medical sciences departments.
Oxford Nanopore’s goal is to enable the analysis of any living thing, by anyone,anywhere. The Company has developed the world's first and only nanopore DNA sequencing platform, which is uniquely scalable from pocket-sized formats through to ultra-high throughput devices.
Oxford Investment Consultants LLP is an investment advisor that covers life sciences, healthcare and technology in the United Kingdom. The firm prefers to make investments in the University of Oxford spin out companies. Oxford Investments Consultants LLP is based in the United Kingdom.
Financing Co-Led by ARCH Venture Partners and Cowen Healthcare Investments Deep Leadership Expertise in Thyroid Hormone Biology, Medicinal Chemistry and Neurology
Read more ›
26th May 2020, Oxford, Copenhagen, and Hamburg – Exscientia, the world leading artificial intelligence (AI) drug discovery company, today announced it has raised $60 million in a Series C financing round. The financing round has been led by new investor Novo Holdings with existing investors – Evotec, Bristol Myers Squibb, and GT Healthcare Capital (through its LPs) – participating in the round. Robert Ghenchev, Senior Partner and Head of Novo Growth, the growth equity arm of Novo Holdings, joins Exscientia’s board of directors as part of the financing round.
Read more ›
Public Sector Pension Investment Board (PSP Investments), a large, Canada-based pension investment manager focused on long-term investments, led the funding, according to a news release. Existing investors TPG’s The Rise Fund, KCK Group, Sofinnova Partners, Venrock, T. Rowe Price, Pfizer Ventures and Johnson & Johnson Innovation, JJDC Inc. all participated in the round. BofA Securities and Morgan Stanley acted as placement agents.
Read more ›
